Key Takeaways
- • McKesson Corp. and private equity firm Clayton Dubilier & Rice (CD&R) have agreed to acquire home infusion services provider Option Care Health for $5.8 billion at $32.05 per share, taking the company private.
- • McKesson will invest approximately $1.4 billion for a 49% minority stake, with the right to purchase additional equity, while CD&R leads the acquisition as the controlling partner.
- • Option Care Health, a Nasdaq-listed provider of at-home infusion therapy services, represents a strategic expansion into home-based healthcare delivery for both McKesson and CD&R.
- • The transaction combines McKesson's healthcare distribution and services expertise with CD&R's operational capabilities to enhance the infusion services platform and improve patient care delivery and cost efficiency.
Summary
McKesson Corp. and Clayton Dubilier & Rice have agreed to acquire Option Care Health Inc., a leading provider of home infusion therapy services, in a $5.8 billion transaction announced in October 2026. The deal values the company at $32.05 per share and will take Option Care Health private, removing it from Nasdaq listing.
Under the transaction structure, McKesson will invest approximately $1.4 billion to acquire a 49% minority interest in Option Care Health, with contractual rights to purchase additional equity positions in the future. CD&R serves as the controlling shareholder and lead acquirer, bringing its private equity operational expertise to optimize the business. The partnership between the healthcare distribution giant and the established buyout firm creates a complementary combination designed to strengthen Option Care Health's market position in the high-growth home-based infusion services sector.
Option Care Health operates as the leading provider of at-home infusion therapy services, focused on improving quality of patient care while reducing overall healthcare costs through home-based delivery models. The acquisition reflects broader industry consolidation in home healthcare services, where McKesson's established healthcare infrastructure and supply chain capabilities combine with CD&R's operational and strategic resources. The transaction is expected to enhance service delivery, expand the infusion therapy platform, and capitalize on increasing demand for cost-effective, patient-centric home-based healthcare solutions.
Under the transaction structure, McKesson will invest approximately $1.4 billion to acquire a 49% minority interest in Option Care Health, with contractual rights to purchase additional equity positions in the future. CD&R serves as the controlling shareholder and lead acquirer, bringing its private equity operational expertise to optimize the business. The partnership between the healthcare distribution giant and the established buyout firm creates a complementary combination designed to strengthen Option Care Health's market position in the high-growth home-based infusion services sector.
Option Care Health operates as the leading provider of at-home infusion therapy services, focused on improving quality of patient care while reducing overall healthcare costs through home-based delivery models. The acquisition reflects broader industry consolidation in home healthcare services, where McKesson's established healthcare infrastructure and supply chain capabilities combine with CD&R's operational and strategic resources. The transaction is expected to enhance service delivery, expand the infusion therapy platform, and capitalize on increasing demand for cost-effective, patient-centric home-based healthcare solutions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.